Affibody’s business is based on two proprietary technology platforms: Affibody® molecules and Albumod™. 

Affibody® molecules can be designed to bind specifically to a large number of target proteins that play an important role in the treatment or diagnosis of disease. Affibody is also commercializing Albumod™, its unique albumin binding technology designed to extend the half-life of any biotherapeutic.

The near term strategy is to establish Affibody as a partner to leading industry players through collaborations based on Affibody's proprietary technology platforms, the company’s unique skills and its expertise.

In parallel, the company will continue building its strong IP-platform.